IRF4 and plasma cell myeloma: Overexpression of IRF4 has been implicated in oncogenicity in multiple myeloma [59], the activated B cell-like subtype of diffuse large B cell lymphomas [60], primary effusion lymphoma [61] and peripheral T-cell lymphomas [62].